Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 2Plasma cell 1

Conditions

Leukemia 33Leukemia, Lymphocytic, Chronic, B-Cell 26Lymphoma 19Myelodysplastic Syndromes 16Hodgkin Disease 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Multiple Myeloma 10Leukemia, Myeloid, Acute 10Lymphoma, Non-Hodgkin 8Lymphoma, Mantle-Cell 7Lymphoma, Follicular 7Recurrence 6Myeloproliferative Disorders 6Lymphoma, Large B-Cell, Diffuse 6Leukemia, Myeloid, Chronic-Phase 6Lymphoma, B-Cell, Marginal Zone 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Hematologic Neoplasms 5Waldenstrom Macroglobulinemia 4Neoplasms, Plasma Cell 4Lymphoma, T-Cell, Cutaneous 4Congenital Abnormalities 4Burkitt Lymphoma 4Anemia, Aplastic 4Sezary Syndrome 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic-Myeloproliferative Diseases 3Mycosis Fungoides 3Lymphoma, T-Cell, Peripheral 3Lymphoma, Large-Cell, Immunoblastic 3

Interventions

blinatumomab 6Cyclophosphamide 5Rituximab 4Tacrolimus 3ponatinib 2fludarabine 2denileukin diftitox 2Vorinostat 2Vincristine 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Methotrexate 2Everolimus 2Etoposide 2Doxorubicin 2Darbepoetin alfa 2Cytarabine 2Busulfan 2Brentuximab Vedotin 2Antilymphocyte Serum 2Alemtuzumab 2tetulomab tetraxetan lu-177 1ruxolitinib 1pembrolizumab 1pegaspargase 1ibrutinib 1ibritumomab tiuxetan 1fludarabine phosphate 1ferrous sulfate 1ferric gluconate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Lymphoproliferative Disorders × Alemtuzumab × Clear all
NCT00368355 2020-01-21

MOHEL

Baylor College of Medicine

Phase 2 Completed
46 enrolled 12 charts
LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphohistiocytosis, Hemophagocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00579111 2016-05-04

Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)

Baylor College of Medicine

Phase 1/2 Terminated
4 enrolled 8 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hematologic Diseases, Lymphoproliferative Disorders, Multiple Myeloma, Myeloproliferative Disorders, Paraproteinemias, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡